april 15 to 17, 2018, halifax, ns€¦ · symposium participants will be treated to an authentic...

2018SYMPOSIUM

Managing Health Technologies: Supporting Appropriate, Affordable, and Accessible Care

April 15 to 17, 2018, Halifax, NS

1

2018 SYMPOSIUM

A WELCOME MESSAGE FROM DR. BRIAN O’ROURKEWelcome to the 2018 CADTH Symposium — Canada’s premier forum for sharing knowledge and gaining insight on the future of health technology management.

It has been eight years since we last held the Symposium in Halifax, one of my favourite Canadian cities. I was born here, studied at Dalhousie University, and worked here early in my career. It is always a pleasure to return, but I am especially proud to be here to celebrate Dalhousie’s 200th anniversary.

Our theme for the 2018 Symposium — Managing Health Technologies: Supporting Appropriate, Affordable, and Accessible Care — recognizes that the evolution of health technology assessment to health technology management is underway and our collective progress is fundamental to delivering excellent health care to Canadians.

Patients and decision-makers today face an array of disruptive technologies — CAR T-cell therapy and genetic testing come to mind — that stir hope for better outcomes, but raise stark questions about how we will use them, pay for them, and ensure equitable access to them. And, with the creation of the Advisory Council on the Implementation of National Pharmacare, debate is swirling about what a national pharmacare program could and should look like.

Over the next three days, we will discuss what is being done — and what still needs to be done — to address these issues and more. Through informative workshops, plenary sessions, presentations, and posters, you will have opportunities to share, learn, and forge new connections. We are also proud to once again be officially accredited by Patients Included. We have planned special activities to welcome patients, as well as students, and look forward to delivering an exceptional CADTH Symposium experience.

Once again, welcome to Halifax and enjoy the conference!

Dr. Brian O’Rourke President and CEO, CADTH

2

2018 SYMPOSIUM

THANK YOUWe gratefully acknowledge the contribution of our sponsors to the success of the 2018 CADTH Symposium. This event could not continue to grow and improve without you!

PLATINUM SPONSOR

GOLD SPONSORS

SILVER SPONSORS

BRONZE SPONSORS

We would also like to acknowledge the support of our funders. CADTH’s activities, programs, and services, including the CADTH Symposium, are made possible through financial contributions from Health Canada and the governments of Alberta, British Columbia, Prince Edward Island, Manitoba, New Brunswick, Nova Scotia, Nunavut, Ontario, Saskatchewan, Newfoundland and Labrador, Northwest Territories, and Yukon.

Réseaucanadien pourla déprescription

CanadianDeprescribing

Network

3

2018 SYMPOSIUM

MINI SCHEDULESUNDAY, APRIL 15, 20180800 – 1900 Registration Desk Open Ballroom Level, Foyer

0800 – 0900 Morning Workshop Registration Ballroom Level, Foyer

0900 – 1200 Workshops AM Ballroom Level & Summit Level

1200 – 1300 Afternoon Workshop Registration Ballroom Level, Foyer

1300 – 1600 Workshops PM Ballroom Level & Summit Level

1615 – 1700 Student Meet and Greet Argyle Level, Argyle Suite A3

1615 – 1700 Patient Group Meet and Greet Argyle Level, Argyle Suite A1

1700 – 1900 Welcome Reception and Scientific Poster Exhibition Ballroom Level, Ballroom B1

MONDAY, APRIL 16, 20180730 – 1700 Registration Desk Open Ballroom Level, Foyer

0800 – 0900 Breakfast Ballroom Level, Ballroom B2/B3

0900 – 0930 Official Opening Ballroom Level, Ballroom B2/B3

0930 – 1045 Opening Plenary Ballroom Level, Ballroom B2/B3

1045 – 1115 Refreshment Break Ballroom Level, Ballroom B1

1115 – 1230 Concurrent Sessions Ballroom Level & Summit Level

1230 – 1330 Buffet Lunch Ballroom Level, Ballroom B2/B3




1730 – 2200 Social Event: Dinner at Pier 21 Pier 21

TUESDAY, APRIL 17, 20180700 – 1700 Registration Desk Open Ballroom Level, Foyer

0700 – 0830 Breakfast Ballroom Level & Summit Level

0730 – 0830 Breakfast Sessions Ballroom Level & Summit Level

0845 – 1000 Plenary Session 2 Ballroom Level, Ballroom B2/B3



1145 – 1315 Awards Luncheon Ballroom Level, Ballroom B2/B3



1500 – 1615 Closing Plenary Ballroom Level, Ballroom B2/B3

1615 – 1630 Official Closing Ballroom Level, Ballroom B2/B3

4

2018 SYMPOSIUM

503502501

506507

508

BallroomSalon

Ballroom B2/B3Ballroom B1

Speaker Ready room

Registration

MARKET STREET

ARGYLE STREET

SACKVILLE STREET

PRINCE STREET

BallroomLevel

ArgyleLevel &Atrium

A1

MARKET STREET

ARGYLE STREET

SACKVILLE STREET

PRINCE STREET

ArgyleSuite

A3

ArgyleSuite

5

2018 SYMPOSIUM

614 613

612

611

603 604 605

608

MARKET STREET

ARGYLE STREET

SACKVILLE STREET

PRINCE STREET

SummitLevel

REGISTRATION DESK Ballroom Level, Foyer

WORKSHOPS Ballroom Level & Summit Level

STUDENT MEET AND GREET Argyle Level, Argyle Suite A3

PATIENT GROUP MEET AND GREET Argyle Level, Argyle Suite A1

WELCOME RECEPTION AND SCIENTIFIC POSTER EXHIBITION Ballroom Level, Ballroom B1

PLENARY SESSIONS Ballroom Level, Ballroom B2/B3

AWARDS LUNCHEON Ballroom Level, Ballroom B2/B3

CONCURRENT SESSIONS Ballroom Level & Summit Level

QUIET ROOM Summit Level, Room 614

2018

CA

DTH

SYM

POSI

UM

SPEC

IAL

EVEN

TS

8

2018 SYMPOSIUM

STUDENT MEET AND GREETSunday, April 15 1615 – 1700 Argyle Level, Argyle Suite A3

Students attending the Symposium are invited to meet other student attendees early in the proceedings. A cash bar and light refreshments will be available.

PATIENT GROUP MEET AND GREETSunday, April 15 1615 – 1700 Argyle Level, Argyle Suite A1

Representatives of patient groups attending the Symposium are invited to meet one another early in the proceedings. A cash bar and light refreshments will be available.

WELCOME RECEPTION AND SCIENTIFIC POSTER EXHIBITION Sunday, April 15 1700 – 1900 Ballroom Level, Ballroom B1

The Welcome Reception features scientific posters and the opportunity to meet and talk with the authors about their work. Dr. Terrence Sullivan, Chair of CADTH’s Board of Directors, Dr. Brian O’Rourke, President and CEO of CADTH, and Dr. David Anderson, Dean of Medicine, Dalhousie University, will welcome attendees. A cash bar and light snacks will be available.

OFFICIAL OPENINGMonday, April 16 0900 – 0930 Ballroom Level, Ballroom B2/B3

Dr. Brian O’Rourke, President and CEO of CADTH, will welcome Symposium participants and describe some of the Symposium highlights.

9

2018 SYMPOSIUM

SOCIAL EVENT: DINNER AT PIER 21Monday, April 16 1730 – 2200 Pier 21

Symposium participants will be treated to an authentic Maritime evening of local food and entertainment at Halifax’s famous Pier 21 — the “gateway to Canada” for over one million immigrants and refugees during the last century. Tour the museum before enjoying the “kitchen party” dinner and lively entertainment. Shuttle buses will leave the Halifax Convention Centre at 1730. The last shuttle will leave Pier 21 at 2200. Jeans or other casual attire are recommended for this event.

CADTH RECOGNITION AWARDS LUNCHEONTuesday, April 17 1145 – 1315 Ballroom Level, Ballroom B2/B3

Join us in honouring the 2018 recipients of the Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment and the Dr. Maurice McGregor Award. The winners of our poster competition will also receive their awards at the luncheon. As this is a plated lunch, please arrive promptly.

2018

CA

DTH

SYM

POSI

UM

PLEN

ARY

SES

SIO

NS

14

2018 SYMPOSIUM

OPENING PLENARYHealth Priorities in a Changing Health Care LandscapeApril 16, 2018 0930 – 1045 Ballroom Level, Ballroom B2/B3

In 2016, the federal, provincial, and territorial ministers of health agreed to move ahead on shared health priorities, working collaboratively and guided by the common vision of creating more adaptable, innovative, and affordable health care systems for all Canadians. In this opening plenary, senior policy-makers from across the country will discuss their priorities, including improving health outcomes for Indigenous Canadians, better care in the community, home care, and mental health. They will report on their progress and plans, and discuss the implications of these priorities for patients, the HTA community, and the health system.

John G. Abbott recently worked as a management consultant with the Institute for the Advancement of Public Policy in St. John’s, Newfoundland and Labrador. Previously, he was CEO of the Health Council of Canada in Toronto, and served with the Government of Newfoundland and Labrador as Deputy Minister of Health and Community Services; Assistant Secretary of the Treasury Board; Associate Deputy Minister of Health and Community Services; Chairman and CEO of Newfoundland and Labrador Housing Corporation; Deputy Minister of Works, Services, and Transportation; and Deputy Minister of Municipal and Provincial Affairs. He also worked in the Department of Finance (1980 to 1982), the Intergovernmental Affairs Secretariat (1982 to 1987), and with the Senior Expenditure Review Committee (1987 to 1989). John Abbott’s work as a public-sector executive earned him the Institute of Public Administration of Canada’s (Newfoundland and Labrador Division) Lieutenant Governor Award of Excellence in Public Administration in 1999. In 2012, the Canadian Mental Health Association (Newfoundland and Labrador) awarded him the Dr. Clarence Pottle Award for Outstanding Service to Furthering Mental Health in the province. He holds a bachelor of arts in political science and economics from Memorial University and a master of arts in public administration from Carleton University. He is national treasurer of the Canadian Mental Health Association and recent president of its Newfoundland and Labrador Division. He was chair of the board of directors of the former Health Care Corporation of St. John’s.

15

2018 SYMPOSIUM

Denise Perret was appointed Deputy Minister of the Nova Scotia Department of Health and Wellness on January 16, 2017. Denise has extensive experience in public law, policy development, and management. She served as corporate counsel for Alberta Health, and then as the department’s Assistant Deputy Minister of Strategic Planning and Policy Development. She has also served as Assistant Deputy Minister, Legal Services for Alberta’s Department of Justice and Solicitor General and as Deputy Chief of the Policy Coordination Office in Alberta’s Executive Council. Prior to coming to the Alberta public service, Denise was in-house counsel for the Workers Compensation Board of Alberta’s Appeals Commission. She has worked in private legal practice and served as city solicitor for an Alberta municipality. She has also held several policy and management positions in the Saskatchewan public service. Throughout her career, she has worked with and provided analytical, strategic, and legal advice at an executive leadership level. Denise has a bachelor of laws degree from the University of Alberta and a master of public administration degree from Queen’s University. She received her Queen’s Counsel designation in 2013.

Milton Sussman has served as Deputy Minister of Alberta Health since October 23, 2017. He has served multiple governments in a variety of roles at the highest levels. He was President and Chief Executive Officer of the Winnipeg Regional Health Authority; Chief Operating Officer and Vice-President, Community Health Services; and Vice-President, Long Term Care. He has had a distinguished career with the Manitoba public service serving in roles such as the Clerk of Executive Council and Cabinet Secretary, Deputy Minister of Health and Healthy Living, and Deputy Minister of Family Services and Housing. He holds a bachelor of arts in English literature.

Pauline Dakin (moderator) is the bestselling author of Run, Hide, Repeat: A Memoir of a Fugitive Childhood (Viking/Penguin Random House Canada). For many years she was a trusted voice on health and medical issues as the national health reporter for CBC News. Her reporting and documentary work have been recognized with many regional, national, and international awards. She is a three-time recipient of fellowships from the National Press Foundation in Washington, DC and is a fellow of the Knight Science Journalism program on medical evidence at the Massachusetts Institute of Technology in Cambridge, Massachusetts. She currently teaches journalism at the University of King’s College in Halifax, Nova Scotia, Canada.

18

2018 SYMPOSIUM

PLENARY SESSION 2Beyond Health Technology Assessment: What Does Health Technology Management Mean for Patients and the Health System?April 17, 2018 0845 – 1000 Ballroom Level, Ballroom B2/B3

For close to three decades, health technology assessment (HTA) has been an essential policy tool, informing technology-related decision-making in Canadian health care. However, ongoing fiscal restraints, the proliferation of new medical devices and surgical procedures, the influx of new delivery models, the global trend of patient involvement, and other factors have transformed health care. The result is that conventional HTA no longer meets the needs of decision-makers, which has led to the introduction of health technology management (HTM): a more active process to influence innovation, adoption, and disinvestment decisions throughout the life cycle of technologies to better support health care decision-makers. In this plenary, an expert panel will outline the key aspects of HTM and a respondent panel of key stakeholders will discuss what this new approach will mean for them and for the overall health system.

Dr. Maureen Allen is an emergency medicine physician practicing in rural Nova Scotia. She has been a health care professional for 36 years, beginning her professional career as a nurse. She completed her medical degree and her residency training in family medicine at Memorial University in Newfoundland in 1991, and later completed added competencies in emergency medicine and palliative care. She is actively involved in continuing education programs and provides clinical support to rural Nova Scotians living with chronic pain, substance-use disorders, and life-limiting illnesses. Her clinical interests include promoting continuing education, improving access to end-of-life care for Nova Scotians living in rural communities, and building community capacity to manage substance-use disorders. She has published on the end-of-life use of atomized methadone on the buccal mucosa, and published a framework for addressing complex pain and addiction through the emergency department. Dr. Allen has been actively involved in the development of an opioid treatment program for her community and provides clinical support to colleagues managing complex pain and substance-use disorders. She is “living the dream” in rural Nova Scotia surrounded by the ocean, two children, a husband, and a temperamental cat and docile dog.

19

2018 SYMPOSIUM

Dr. Fiona Clement is nationally recognized as a skilled and passionate leader in evidence-informed health care policy. She is deeply committed to positively affecting the Canadian health policy arena. Her recent work includes:

• conducting a major policy analysis to support an evidence-informed conversation at the provincial, territorial, and federal table to ensure the federal legislation to legalize non-medical cannabis considers the economic aspects, the health risks, the lessons learned from other jurisdictions, and the preferences of Canadians

• designing an approach for Canada that would provide pharmaceutical drug coverage for all citizens without busting the budget; and

• leading an innovative research agenda that could result in millions of health care dollars achieving better value in the system through looking critically at technology use, assessing the clinical outcomes of technologies alongside the costs, and implementing changes in the way the technology is used, if required.

Brian Huskins is an established community leader in patient engagement in the voluntary health care sector. With over 30 years of experience working with community-based health and social organizations, he has served on many advisory committees as a patient representative at the local, provincial, national, and international level. A snapshot of his involvement would include serving as a patient representative on the Consumer Advisory Committee with Canadian Blood Services; as a civil society representative with the Canadian delegation to the United National General Assembly Special Session on HIV/AIDS; serving on the 3x5 Evaluation Steering Committee with the World Health Organization; and providing multiple patient consultations on best practices and access to services with various levels of health administration, government, and organizations focused on the social determinants of health. As an Ontarian living with HIV, asthma, and chronic obstructive pulmonary disease, Brian is familiar with the challenges of the health care system. He engages with a wide variety of health care professionals on a regular basis in the management of these chronic conditions, and maintains a broad network of patient-organization contacts who function on the patient-first principle of “nothing for us without us.” Brian is currently a Senior Fellow of Not-For-Profit Governance with the Institute on Governance in Toronto, specializing in the provision of skills training, board assessments, and capacity development of volunteer directors of social profit organizations. Brian has written about HIV/AIDS, health and social issues for various publications, and has published “Sexual Identity: The Journey Begins” and “Breaking the Skin: Tattooing and Body Piercing — Know the Risks.”

Terri Irwin is the Director of the Quality Standards program at Health Quality Ontario. Ms. Irwin is a nurse with 16 years of experience in cardiac critical care, front-line clinical management, and professional practice within the acute care setting and in standards development and consultation at the College of Nurses of Ontario. She holds a bachelor of science degree in nursing and a master of nursing administration.

20

2018 SYMPOSIUM

Dr. Craig Mitton is a professor in the School of Population and Public Health at UBC and Co-Director (interim) of the Centre for Clinical Epidemiology and Evaluation in Vancouver, British Columbia. Dr. Mitton’s research is focused on the application of health economics to impact health policy and to inform clinical practice. Specific areas of interest include the use of evidence to support health care decision-making, public involvement in priority setting, and mechanisms to support knowledge transfer. He is the lead author on a book titled Priority Setting Toolkit: A Guide to the Use of Economics in Healthcare Decision Making and is the lead or co-author of more than 130 peer-reviewed journal articles. He has delivered over 150 presentations in many different countries and regularly runs workshops on health economics and health care priority setting. In 2015, he was awarded a Killam Teaching Prize from the University of British Columbia (UBC).

YJ Oh is originally from British Columbia and graduated from McGill University with a bachelor of science in physiology before earning her MBA (Dean’s List) at the Rotman School of Management at the University of Toronto. Ms. Oh is currently the Managing Director of Edwards Lifesciences (Canada), the world leader in innovative structural heart therapies and critical-care monitoring. She has over 20 years of commercial leadership experience in both the medical technology and biologic pharmaceutical sectors. Prior to that, she worked in the information technology and insurance sectors. She has been recognized with numerous global awards for her ability to lead cross-functional teams and is known for her ability to take customer insights and to translate them into strategy. She is also on the board of directors for MEDEC. Ms. Oh is a past chair of the Women’s Leadership Initiative (WLI) and was a member of the North American WLI steering committee promoting the advancement of women in management. She is involved with a number of community organizations and is married with three children and resides in Toronto.

Dr. Harindra Wijeysundera (moderator) is CADTH’s Vice-President of Medical Devices and Clinical Interventions. Dr. Wijeysundera is an interventional cardiologist and clinician scientist at the Schulich Heart Centre, Sunnybrook Health Sciences Centre, and associate professor of medicine at the University of Toronto. He is also an adjunct scientist at the Institute for Clinical Evaluative Sciences and cross-appointed to the Institute for Health Policy, Management, and Evaluation at the University of Toronto. Dr. Wijeysundera is a graduate of the Faculty of Medicine at the University of British Columbia and subsequently did specialty training in internal medicine and adult cardiology at the University of Toronto. He also holds a PhD in clinical epidemiology from the University of Toronto.

21

2018 SYMPOSIUM

CLOSING PLENARYAppropriate, Affordable, and Accessible Drug Therapy: Can We Have It All?April 17, 2018 1500 – 1615 Ballroom Level, Ballroom B2/B3

Federal, provincial, and territorial governments across Canada are committed to supporting improvements to Canada’s pharmaceutical systems in the three key areas of appropriate use, affordability, and accessibility. This plenary session will consider whether this is possible or just a pipe dream. In 2015, Canada spent an estimated $34.8 billion on drugs. Gene therapies, combination therapies, and other disruptive technological advances threaten to push costs even higher. Can we have it all, and what changes will be necessary to make that possible?

Sir Andrew Dillon graduated from the University of Manchester in 1975. He has held a number of senior management positions in the UK National Health Service (NHS), including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust in London. He joined the National Institute for Health and Care Excellence (NICE) as its founding Chief Executive in 1999.

Brian Hilberdink Brian Hilberdink is an accomplished executive, with over 20 years of global and domestic experience developing and executing the strategy for Novo Nordisk A/S — one of the world’s largest biotechnology companies. In his current role as President of Novo Nordisk Canada, he has significantly increased investment in Canada; launched several innovative products in the therapy areas of diabetes, obesity, and hemophilia; and the company has been recognized as one of the country’s top 100 employers. Mr. Hilberdink is an active contributor on the Board of Innovative Medicines Canada and BIOTECanada, and is also a founding member of the Diabetes Canada Impact Council and the City of Mississauga’s Life Sciences Consortium. Previous to his current role, Mr. Hilberdink was a Corporate Vice President in Global Marketing for Novo Nordisk A/S in Copenhagen, Denmark, leading the launch of the company’s future insulin portfolio; at the time, this represented the single largest investment ever made in the history of diabetes drug development. He also has experience working in the United States, where he led several commercial teams during a period of significant growth and investment.

22

2018 SYMPOSIUM

Steve Morgan is a professor of health policy in the School of Population and Public Health at the University of British Columbia. He studies policies to promote universal access to appropriately prescribed, affordably priced, and equitably financed medications. Dr. Morgan has published over 150 peer-reviewed research papers and has provided policy advice and expert testimony to governments in Canada and abroad. Dr. Morgan earned degrees in economics from the University of Western Ontario, Queen’s University, and the University of British Columbia. He received post-doctoral training in health policy analysis at McMaster University.

Dr. Marianne Taylor pursued her medical training in Ontario. She completed her MBA at UBC in 2013 and recieved a master’s in Healthcare Quality in 2017. Dr. Taylor has been a practising medical oncologist for 28 years. She held leadership positions at BC Cancer Agency (BCCA) from 2004 to 2016. From 2012 to 2016, she was the Vice-President of Systemic Therapy at the BCCA. At the BCCA, one of her primary responsibilities was managing the provincial cancer drug budget. Dr. Taylor was chair of the CADTH pan-Canadian Oncology Drug Review’s Provincial Advisory Group previously and now sits on the pCODR Expert Review Committee. She is the staff medical oncologist for the Drug Funding Sustainability project at the Canadian Association of Provincial Cancer Agencies.

Janet Yale (moderator) is the President and CEO of the Arthritis Society (Canada). Janet previously served as Executive Vice-President at TELUS and President and CEO of the Canadian Cable Television Association, along with other C-suite roles in private, public, and not-for-profit organizations. Currently, Ms. Yale chairs the Arthritis Alliance of Canada, serves as Past Chair of the Ontario Trillium Foundation, and serves on the boards of Samara and the Ottawa Art Gallery. She is a recipient of the Queen Elizabeth II Diamond Jubilee Medal.

2018

CA

DTH

SY

MPO

SIUM

SCH

EDUL

E

26

2018 SYMPOSIUM

SCHEDULESUNDAY, APRIL 15, 20180800 – 1900 Registration Desk Open Ballroom Level, Foyer

0800 – 0900 Morning Workshop Registration Ballroom Level, Foyer

0900 – 1600 Workshop FD–1 (Full Day) Ballroom Level, Room 503An Introduction to Health Technology AssessmentIntroductory. Will be of particular interest to patients, students, and people new to health technology assessment (HTA).Educational objective: Participants will gain an understanding of the components and conduct of high-quality HTAs, from defining research questions to addressing implementation issues. • Dr. Jean-Eric Tarride, McMaster University• Dr. Mitchell Levine, McMaster University• Prof. Daria O’Reilly, McMaster University• Dr. Bernice Tsoi, CADTH

0900 – 1200 Workshop AM-1 Summit Level, Room 612/613Clearer Communication and Plain-Language Writing: Making Health Research Make SenseIntermediate. Will be of interest to all audiences.Educational objective: Participants will leave with the plain-language skills needed to explain research and complex health topics clearly to people who may not have a technical background.• Dr. Janice Mann, CADTH

Workshop AM-2 Summit Level, Room 603/604Oncology’s Next Top Model: Survival Extrapolation Methods Under the Spotlight Intermediate. Will be of particular interest to HTA producers.Educational objective: Through problem-based learning, you will deepen your understanding of the complex challenges associated with modelling survival outcomes in oncology. Participants will debate, apply, and assess the impact of the use of different methodological approaches.• Dr. Jeffrey Hoch, University of California• Jaclyn Beca, Cancer Care Ontario• Dr. Petros Pechlivanoglou, The Hospital for Sick Children• Julian Nam, Hoffmann-La Roche

Workshop AM-3 Ballroom Level, Room 501/502Rapid Reviews: From Policy Question to Research and Decision-MakingIntermediate. Will be of particular interest to decision-makers, HTA producers, and those involved in dissemination and implementation efforts.Educational objective: To provide an introduction to CADTH Rapid Reviews and how they are used in decision-making, and to explore how they can be improved to meet the needs of decision-makers.• Chris Kamel, CADTH• Danielle Rabb, CADTH• Lisa Farrell, CADTH

27

2018 SYMPOSIUM

SUNDAY, APRIL 15, 20180900 – 1200 Workshop AM-4 Summit Level, Room 614

Developing, Implementing, and Evaluating Roles for Community Pharmacists in Mental Illness and Addictions CareIntermediate. Will be of particular interest to patients, policy-makers, and health care professionals.Educational objective: To discuss and analyze existing and potential roles for community pharmacists in mental health care by using participatory-action research techniques to elicit participants’ challenges and opportunities in caring for the mental health of communities.• Dr. Andrea Murphy, Dalhousie University• Dr. David Gardner, Dalhousie University

Workshop AM-5 Summit Level, Room 608/609Is Your Intervention Cost-Effective in the Real World? The Role of Economic Evaluation Using Person-Level DataIntermediate. Will be of particular interest to researchers, HTA producers, and health care professionals.Educational objective: Participants will gain an understanding of the concepts and potential roles of person-level data in economics and work through examples of how to conduct economic evaluations using person-level data from clinical trials, observational studies, or administrative databases.• Dr. Wanrudee Isaranuwatchai, Centre for Excellence in Economic Analysis

Research, St. Michael’s Hospital• Dr. Kednapa Thavorn, The Ottawa Hospital Research Institute

Workshop AM-6 Ballroom Level, Room 506/507The Role of and Developments in Database Search Filters in Health Technology AssessmentIntroductory. Will be of particular interest to information specialists, health librarians, and others interested in retrieving evidence-informed health information.Educational objective: Participants will learn what database filters are, why they are important for HTA and systematic reviews, where to find reliable filters, what the best practices are for database search filters, how filters are developed, and what the current trends are.• Sarah McGill, CADTH

Workshop AM-7 Summit Level, Room 611How Can Policy-Makers and Clinicians Trust the Results of a Network Meta-Analysis? A Workshop on How to Apply the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ToolIntermediate. Will be of particular interest to policy-makers and health care professionals.Educational objective: Participants will be able to determine: the appropriateness of a network meta-analysis for their decision-making, the validity and applicability of network meta-analyses, and how to apply the ISPOR tool.• Dr. Andrea Tricco, Li Ka Shing Knowledge Institute, St. Michael’s Hospital

1200 – 1300 Afternoon Workshop Registration Ballroom Level, Foyer

1200 – 1400 Roundtable: Insights and Opportunities for Improving Mental Health in CanadaHosted by the CADTH Mental Health & Addictions Working Group, the roundtable will bring practitioners, researchers, policy-makers, patient advocates, and students together with people living with mental health problems to identify priority areas and key issues within mental health. Lunch will be provided. By invitation only; if you are interested in attending, please send an email to [email protected].

28

2018 SYMPOSIUM

SUNDAY, APRIL 15, 20181300 – 1600 Workshop PM-1 Summit Level, Room 612/613

Introduction to the Design of Markov Models for Economic EvaluationIntermediate. Will be of particular interest to decision-makers, HTA producers, and researchers.Educational objective: Participants will leave with a thorough understanding of the key components of a Markov model and an introduction on how to develop probabilistic Markov models using Microsoft Excel.• Dr. Doug Coyle, University of Ottawa• Karen Lee, CADTH

Workshop PM-2 Summit Level, Room 614Making Tough Decisions: An Interactive Deliberative ExerciseIntroductory. Will be of particular interest to patients, students, and those who are new to HTA.Educational objective: To provide an understanding of the various aspects of value used in drug-funding recommendations and to identify and discuss additional information that might assist decision-making.• Sarah Berglas, CADTH• Ken Bond, CADTH• Anthony Budden, CADTH• Marina Richardson, CADTH

Workshop PM-3 Ballroom Level, Room 501/502Fast-Forward, Pause, Rewind: Applied Critical Appraisal in the Drug Product Life CycleIntermediate. Will be of particular interest to health care professionals and policy-makers.Educational objective: Participants will learn how to assess and appraise the evidence used to support drug-review recommendations, evaluate the real-world implications of formulary recommendations on prescribing patterns, and interpret post-listing evidence and the resulting need for policy change.• Dr. Jamie Falk, University of Manitoba• Dr. Shawn Bugden, University of Manitoba

Workshop PM-4 Summit Level, Room 608/609Using the Media to Drive Evidence-Based ChangeIntroductory. Will be of interest to all audiences.Educational objective: To provide strategies and practical exercises to help you write sharp evidence-based articles and op-ed pieces for broad audiences through mainstream media and newsletters.• Shannon Sampert, EvidenceNetwork.ca and University of Winnipeg

29

2018 SYMPOSIUM

SUNDAY, APRIL 15, 20181300 – 1600 Workshop PM-5 Summit Level, Room 603/604

Accelerating Innovation for Enhancing Health Care Through Effective Health Technology ManagementIntroductory. Will be of particular interest to policy-makers.Educational objective: This workshop will explore challenges to the development and implementation of health system innovations in Canada, provide participants with insights into current knowledge-translation and implementation-science approaches, and offer an opportunity to co-design policy solutions.• Dr. Don Juzwishin, Alberta Health Services• Brendalynn Ens, CADTH• Dr. Josephine McMurray, Wilfrid Laurier University• Maggie MacNeil, University of Waterloo• Dr. Rosalie Wang, University of Toronto• Dr. Michael Wilson, McMaster University• Kevin Harter, York Care Centre• Dr. Jeff Jutai, University of Ottawa• Jenna Roddick, AGE-WELL

Workshop PM-6 Summit Level, Room 611Applying Different Study Designs for Comparative Effectiveness Research in Health Technology AssessmentIntermediate. Will be of particular interest to researchers and HTA producers.Educational objective: To introduce different study designs for comparative effectiveness and their application in HTA, and to discuss real-world examples of the use of different study designs in HTA, their strengths and weaknesses, and important methodological considerations.• Dr. Lusine Abrahamyan, University of Toronto• Dr. Valeria Rac, Toronto Health Economics and Technology Assessment (THETA) Collaborative,

Toronto General Hospital Research Institute and University of Toronto

Workshop PM-7 Summit Level, Room 605A Users’ Guide to Qualitative-Evidence SynthesisIntroductory. Will be of particular interest to policy-makers.Educational objective: Participants will gain an understanding of when and how qualitative-evidence synthesis can be used in HTA to support decision-making.• Andrea Smith, CADTH• Dr. Laura Weeks, CADTH• Elijah Herington, CADTH• Dr. Deirdre DeJean, University of Ottawa

Workshop PM-8 Summit Level, Room 506/507Living Systematic ReviewsIntermediate. Will be of particular interest to HTA producers, systematic review authors, and coordinators.Educational objective: Participants will gain a practical understanding of review methods for living systematic reviews (LSRs): when an LSR is appropriate, the implications for review production and processes, and what needs to be considered when undertaking a living review.• Sathya Karunananthan, The Ottawa Hospital Research Institute• Katrina Sullivan, The Ottawa Hospital Research Institute

1615 – 1700 Student Meet and Greet Argyle Level, Argyle Suite A3Students attending the Symposium are invited to meet other student attendees early in the proceedings. There will be a cash bar and light refreshments.

30

2018 SYMPOSIUM

SUNDAY, APRIL 15, 20181615 – 1700 Patient Group Meet and Greet Argyle Level, Argyle Suite A1

Representatives of patient groups attending the Symposium are invited to meet one another early in the proceedings. There will be a cash bar and light refreshments.

1700 – 1900 Welcome Reception and Scientific Poster Exhibition Ballroom Level, Ballroom B1• Dr. Brian O’Rourke, President and CEO, CADTH• Dr. Terrence Sullivan, Chair, CADTH Board of Directors• Dr. David Anderson, Dean of Medicine, Dalhousie University

32

2018 SYMPOSIUM

MONDAY, APRIL 16, 2018

0730 – 1700 Registration Desk Open Ballroom Level, Foyer

0800 – 0900 Breakfast Ballroom Level, Ballroom B2/B3

0900 – 0930 OFFICIAL OPENING Ballroom Level, Ballroom B2/B3• Dr. Brian O’Rourke, President and CEO, CADTH

0930 – 1045 OPENING PLENARY Ballroom Level, Ballroom B2/B3Health Priorities in a Changing Health Care Landscape• John Abbott, Deputy Minister, Department of Health & Community Services, Government of

Newfoundland and Labrador• Pauline Dakin, Assistant Professor, University of King’s College• Denise Perret, Deputy Minister, Department of Health and Wellness, Government of Nova Scotia• Milton Sussman, Deputy Minister, Alberta Health, Government of Alberta


1115 – 1230 Concurrent Session A1 — Panel Discussion Summit Level, Room 612/613Health Technology Management and Value-Based Procurement in Medical Devices: A Convergence of Two Worlds?• Dave Duerr, Johnson & Johnson Medical Device Companies• William Charnetski, Ontario Ministry of Health and Long-Term Care• Dr. Harindra Wijeysundera, CADTH

Concurrent Session A2 — Panel Discussion Ballroom Level, Room 501/502An Overview of a Provincial “Appropriateness of Care” Initiative: A Provincial Collaborative Supporting Appropriate, Affordable, and Accessible Care• John Abbott, Deputy Minister, Department of Health and Community Services, Government of

Newfoundland and Labrador• Dr. Edward Randell, Department of Health and Community Services, Government of

Newfoundland and Labrador• Deena Waddleton, Department of Health and Community Services, Government of

Newfoundland and Labrador• Sheila Tucker, CADTH

Concurrent Session A3 — Panel Discussion Summit Level, Room 608/609Real-World Data and Evidence for Decision-Making to Improve Access to and Appropriateness and Affordability of Innovative Medicines for Canadians• Dr. Jeffrey Hoch, University of California• Dr. Shane Woods, Flatiron Health• Dr. Paul Terry, PHEMI

Concurrent Session A4 — Panel Discussion Summit Level, Room 611Deprescribing by Policy• Prof. David Gardner, Dalhousie University• Dr. Cara Tannenbaum, University of Montreal• Dr. Andrea Murphy, Dalhousie University• Dr. Justin Turner, Centre de recherche de l’Institut universitaire de gériatrie de

Montréal (CRIUGM)• Kathleen Coleman, Nova Scotia Department of Health and Wellness• Dr. Patricia Caetano, Government of Manitoba

33

2018 SYMPOSIUM


1115 – 1230 Concurrent Session A5 — Panel Discussion Ballroom Level, Room 506/507Patient Assistance Programs For Patient Access or Market Access?• Dr. Elaine Chong, Ministry of Health, Government of British Columbia• Shirin Rizzardo, Ministry of Health, Government of British Columbia• Dr. Eric Lun, Ministry of Health, Government of British Columbia

Concurrent Session A6 – Panel Discussion Summit Level, Room 605Placing Data Within a Knowledge-Based Healthcare and Social Services System: A Growing Experience for INESSS• Michèle Archambault, INESSS• Mike Benigeri, INESSS• Sylvie Bouchard, INESSS• Laurie Lambert, INESSS• Carl Drouin, INESSS

Concurrent Session A7 – Panel Discussion Summit Level, Room 603/604Enhancing the Management of Pharmaceuticals in Canada • Heather Logan, CADTH• Tanya Potashnik, Patented Medicine Prices Review Board• Kathy Gesy, Saskatchewan Cancer Agency• Megan Bettle, Health Canada• Imran Ali, Senior Manager, pan-Canadian Pharmaceutical Alliance Office

1230 – 1330 Buffet Lunch Ballroom Level, Ballroom B2/B3

1330 – 1445 Concurrent Session B1 — Oral Presentations Summit Level, Room 603/604HOT TOPICSSystem Planning for Breakthrough Therapies: Don’t Put the CART Before the Horse• Lisa Milgram, Cancer Care Ontario

Will Parallel Regulatory and Health Technology Assessment Review Processes Reduce Access Time for Patients in Canada?• Dr. Lawrence Liberti, Centre for Innovation in Regulatory Science

Post-Market Outcome for Pharmaceuticals: Challenges and Opportunities• Dr. Mofakhar Hussain, University of Toronto

Under the Hood of Product Listing Agreements (PLA): the Non-Insured Health Benefits Program’s Automated PLA Invoicing• Andrew Portolesi, Non-Insured Health Benefits Program, Department of Indigenous Services

Canada

Concurrent Session B2 — Oral Presentations Ballroom Level, Room 503BEYOND TRADITIONAL HEALTH TECHNOLOGY ASSESSMENTHealth Technology Assessment Designed by Decision-Makers for Decision-Makers: The Case of Transoral Robotic Surgery• Dr. Tania Stafinski, University of Alberta

Thinking Explicitly About Ethical Issues• Ken Bond, CADTH

Quality Standards and Health Technology Assessment: How This Dynamic Duo Works in Concert to Drive Evidence-Based Decision-Making in Ontario• Terri Irwin, Health Quality Ontario

34

2018 SYMPOSIUM


1330 – 1445 Concurrent Session B3 — Oral Presentations Summit Level, Room 608/609MEDICAL DEVICES — DECISION-MAKINGNon-Drug Health Technology Decision-Making in Canadian Health Institutions• Prof. Devidas Menon, University of Alberta

A Framework for Supporting Timely Decision-Making in a Context of Promise and Uncertainty• Geneviève Plamondon, Institut national d’excellence en santé et en services sociaux (INESSS)

An Evaluation That Aims to Optimize the Shared Decision-Making Process About Defibrillator Replacement: A Multi-Method Approach• Laurie Lambert, INESSS

Concurrent Session B4 — Oral Presentations Summit Level, Room 608/609DRUG EXPENDITURESForecasting Ontario Provincial Drug Expenditures: A Hybrid Approach to Improving Accuracy• Luciano Ieraci, Cancer Care Ontario• Thomas Shin, Cancer Care Ontario

The Cost of New Oral Antidiabetes Drugs in Canada and Internationally • Nevzeta Bosnic, Patented Medicine Prices Review Board

Predictors of Public Payer Reimbursement for Orphan Drugs in Canada, Europe, and Australia • Dr. Larry Lynd, University of British Columbia

Concurrent Session B5 — Oral Presentations Ballroom Level, Room 506/507HEALTH TECHNOLOGY ASSESSMENT METHODSApplying a Mixed-Methods Framework in User-Centred Design and Usability Testing of Mobile Health Interventions• Meshari Alwashmi, Memorial University

When the Wheel Doesn’t Need Reinventing: Updating a Cochrane Systematic Review to Inform a CADTH Health Technology Assessment• Sara Khangura, CADTH

Bridging the PATHway From Health Technology Assessment to Health Technology Management: A Comprehensive Approach to the Evaluation of Medical Devices• Prof. Daria O’Reilly, McMaster University

Linking Low-Value Care Lists and Administrative Data to Prioritize Health Technologies for Reassessment• Lesley Soril, University of Calgary

Concurrent Session B6 — Oral Presentations Summit Level, Room 605KNOWLEDGE MOBILIZATION AND IMPLEMENTATION SUPPORTTranslating the KidneyWise Clinical Toolkit into an Electronic Medical Records Decision-Support Tool: An Innovative and Practical Strategy for Primary Care Providers• Dr. Allan Grill, Ontario Renal Network• Stephanie Chin, eHealth Centre of Excellence

A Methotrexate Educational Resource — Patient to Patient: Helping to Manage the Challenges of Methotrexate Treatment for Patients With Inflammatory Arthritis• Linda Wilhelm, Canadian Arthritis Patient Alliance

Can an Education Module Encourage Obstetrics/Gynecology Resident Physicians to Include Cost Awareness in Their Decision-Making? Report of a Randomized Trial• Dr. Sue Ross, University of Alberta

35

2018 SYMPOSIUM


1330 – 1445 Concurrent Session B7 — Oral Presentations Ballroom Room, Room 501/502PATIENT AND PUBLIC ENGAGEMENTUnderstanding the Perspectives of Patients’ and Family Members’ Experience With Treatment: Engaging Patients in the Medical Devices and Clinical Interventions Portfolio at CADTH• Tamara Rader, CADTH• Andrea Smith, CADTH

Managing Screening Technologies in the Face of Uncertainty: Results From a Population Survey and Deliberations With Ontario Citizens • Dr. Julia Abelson, McMaster University

Co-Designing and Conducting a Scoping Review With Patients• Tamara McCarron, University of Calgary

Making Fair and Sustainable Decisions About Funding for Cancer Drugs in Canada• Dr. Stuart Peacock, Canadian Centre for Applied Research in Cancer Control

Concurrent Session B8 — Oral Presentations Summit Level, Room 611HEALTH ECONOMICS METHODSA New Conceptual Model of the Cost-Effectiveness Threshold• Dr. Mike Paulden, University of Alberta

Using Theory to Assist Guidance: The Case of the Canadian Guidelines for Economic Evaluation • Dr. Doug Coyle, University of Ottawa

Patient Prioritization in Disease-Specific-Treatment Budgets• Dr. Lauren E. Cipriano, Western University

Estimating Transition Probabilities for a Three State Markov Model from Published Kaplan-Meier Curves• Dr. Eldon Spackman, University of Calgary.


1515 – 1630 Concurrent Session C1 — Panel Discussion Summit Level, Room 603/604The Growing Cost of Oncology Drugs: Is It Sustainable?• Scott Gavura, Cancer Care Ontario• Alexandra Chambers, CADTH• Tanya Potashnik, Patented Medicine Prices Review Board• Elena Lungu, Patented Medicine Prices Review Board• Dr. Tallal Younis, Dalhousie University• Sherry O’Quinn, MORSE Consulting

Concurrent Session C2 — Panel Discussion Ballroom Level, Room 501/502HTA for Indigenous Decision-Makers: What Is Needed? What Is Appropriate?• Jeannette Smith, CADTH• Jocelyn Chisamore, CADTH• Brent Young, Dalhousie University• Dr. Rose Roberts, University of Saskatchewan• Shelley Francis, University of New Brunswick

Concurrent Session C3 — Panel Discussion Summit Level, Room 612/613Essential Medicines in Canada: What Is Essential, and How Accessible Is It?• Dr. Nav Persaud, St. Michael’s Hospital and University of Toronto• Nevzeta Bosnic, Patented Medicine Prices Review Board

36

2018 SYMPOSIUM


1515 – 1630 Concurrent Session C4 — Panel Discussion Ballroom Level, Room 503What Is It to “Think Qualitatively” Within Health Technology Assessments?• Elijah Herrington, CADTH• Prof. Janice Graham, Dalhousie University• Dr. Jeremy Petch, Li Ka Shing Knowledge Institute, St. Michael’s Hospital• Andrea Smith, CADTH

Concurrent Session C5 — Panel Discussion Summit Level, Room 612/613Patients, Patient Groups, and Patient Engagement: Blockbuster or Boondoggle? • Dr. Sharon Batt, Dalhousie University• Kevin McNamara, retired (former Deputy Minister of Health, Government of Nova Scotia)• Bill Swan, Faces of Pharmacare• Dr. Dilini Vethanayagam, University of Alberta• Kerri MacKay, Patient Advisors Network• Dia Sue-Wah-Sing, Canadian Severe Asthma Network

Concurrent Session C6 — Panel Discussion Summit Level, Room 605Evidence-to-Action: Canadian Medical Imaging Inventory• Dr. Harindra Wijeysundera, CADTH• Susan Delaney, Nova Scotia Health• Tanya Dickey, Health PEI• Karren Fader, CAMRT• Andra Morrison, CADTH• Lisa Pyke, CADTH• Kasia Kaluzny, CADTH

Concurrent Session C7 — Panel Discussion Summit level, Room 611Using Health Care Administrative and Other Real-World Data Sources for Decision-Making: What Role for Health Technology Assessment?• Janey Shin, Janssen• Dr. Kelvin Chan, Odette Cancer Centre, Sunnybrook Health Sciences Centre• Doug Manuel, Institute for Clinical Evaluative Sciences• Don Husereau, University of Ottawa

Concurrent Session C8 – Panel Discussion Ballroom Level, Room 506/507Collaborative HTA: The Whole is Greater Than the Sum of its Parts• Gino De Angelis, CADTH• Lesley Dunfield, CADTH• Sarah McDowell, Health Quality Ontario• Vivian Ng, Health Quality Ontario• Nancy Sikich, Health Quality Ontario• Andree Mitchell, Health Quality Ontario• Dr. Bernice Tsoi, CADTH• Dr. Laura Weeks, CADTH

1730 – 2200 Social Event: Dinner at Pier 21Join us for an authentic Maritime evening of local food and entertainment at Halifax’s famous Pier 21.Buses leave from the Halifax Conference Centre at 1730.

38

2018 SYMPOSIUM

TUESDAY, APRIL 17, 2018

0700 – 1700 Registration Desk Open Ballroom Level, Foyer

0700 – 0830 Breakfast Ballroom Level & Summit Level

0730 – 0830 Breakfast Session 1 Summit Level, Room 605Medical Devices: Overview of Epidemiologic and Qualitative Research on Recalls, Decision-Making, and Adverse-Event Reporting in Canada• Prof. Anna Gagliardi, University Health Network and University of Toronto

Breakfast Session 2 Summit Level, Room 611Wax On, Wax Off. Wax On, Wax Off: A Rapid Mentorship Session on How to Succeed in Health Technology Assessment• Shannon Kelly, PhD Student, University of Ottawa• Dr. Jean-Eric Tarride, McMaster University• Dr. Laura Weeks, CADTH• Dr. Ingrid Sketris, Dalhousie University• Dr. George Wells, University of Ottawa Heart Institute

Breakfast Session 3 Summit Level, Room 608/609National Pain Strategy Development — Rationale and Process: Exemplars From Other Fields• Dr. Owen Williamson, President, Pain Medicine Physicians of BC Society

Breakfast Session 4 Summit Level, Room 612/613What Medicines Are Essential in Canada?• Dr. Nav Persaud, St. Michael’s Hospital and University of Toronto

Breakfast Session 5 Ballroom Level, Room 501/502Medical Cannabis: Equal Access for All?• Philippe Lucas, Tilray• Dr. Bruno Battistini, New Brunswick Health Research Foundation• Jonathan Zaid, Canadians for Fair Access to Medical Marijuana• Johnny Ma, Mapol

Breakfast Session 6 Ballroom Level, Room 506/507An EXCITE-ing Process for Evaluating Medical Devices: The Case of Continuous Glucose Monitoring in Type 1 Diabetes• Dr. Cheryl Pritlove, St. Michael’s Hospital• Lisa Masucci, St. Michael’s Hospital• Shahira Bhimani, MaRS EXCITE• Ruth Pichora, Medtronic

Breakfast Session 7 Ballroom Level, Room 503Dalhousie Academic Detailing Service: From Vision to Visit• Isobel Fleming, Dalhousie University• Pam McLean-Veysey, Dalhousie University• Dr. Edie Baxter, Dalhousie University

Breakfast Session 8 Summit Level, Room 603/604Proposed Changes to Canada’s PMPRB Budget Impact Analysis Guidelines for New Drug Submissions to Public and Private Payers• Naghmeh Foroutan, McMaster University• Fergal Mills, Innomar Consulting

39

2018 SYMPOSIUM


0845 – 1000 PLENARY SESSION Ballroom Level, Ballroom B2/B3Beyond Health Technology Assessment: What Does Health Technology Management Mean for Patients and the Health System?• Dr. Maureen Allen, Emergency Medicine Physician• Dr. Fiona Clement, Director of the Health Technology Assessment and Appraisal Unit and

Assistant Professor, University of Calgary• Brian Huskins, Patient and Public Representative, Ontario Health Technology Advisory Committee• Terri Irwin, Director, Quality Standards, Health Quality Ontario• Dr. Craig Mitton, Professor, Health Services and Policy Branch, Faculty of Medicine, University of

British Columbia• YJ Oh, Managing Director, Edwards Lifesciences (Canada) Inc.• Dr. Harindra Wijeysundera, Vice-President, Medical Devices and Clinical Interventions, CADTH


1030 – 1145 Concurrent Session D1 — Oral Presentations Summit Level, Room 612/6123REAL-WORLD EVIDENCECould We Measure the Cost-Effectiveness of an Intervention Before We Know Its Effect? Early Health Technology Assessment Using Real-World Data• Sasha van Katwyk, The Ottawa Hospital Research Institute

Developing a Framework for the Incorporation of Real-World Evidence Into Cancer Drug–Funding Decisions in Canada• Dr. Kelvin Chan, Odette Cancer Centre, Sunnybrook Health Sciences Centre

A Coordinated Approach to Implanting a Promising Therapy: Thrombectomy for Ischemic Stroke• Laurie Lambert, Institut national d’excellence en santé et en services sociaux (INESSS)

Concurrent Session D2 — Oral Presentations Ballroom Level, Room 501/502PRECISION MEDICINEEconomic Evaluations of Next-Generation Precision Oncology: A Critical Review• Deirdre Weymann, British Columbia Cancer Agency

Randomized Controlled Trial of a Decision Aid for the Selection of Incidental Genome Sequencing Results• Dr. Yvonne Bombard, Li Ka Shing Knowledge Institute, St. Michael’s Hospital

Next-Generation Sequencing and the Return of Secondary Findings for Colorectal Cancer Syndromes: A Cost-Effectiveness and Value-Based Framework Analysis• Dr. Dean Regier, BC Cancer Agency

Understanding Preferences for Genomics-Guided Lymphoid Cancer Management: Results From Patient Focus Groups• Sarah Costa, Canadian Centre for Applied Research in Cancer Control

Concurrent Session D3 — Oral Presentations Ballroom Level, Room 506/507ECONOMIC EVALUATIONS — MEDICAL DEVICESAn Economic Evaluation of the National Surgical Quality Improvement Program (NSQIP) in Alberta, Canada• Dr. Thanh Nguyen, Institute of Health Economics

Cost-Effectiveness of Remote Monitoring of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy Defibrillators• Man Wah Yeung, Health Quality Ontario

Improving “Cost Awareness” in Laparoscopic Hysterectomy at the Lois Hole Hospital for Women: Effect on Cost of Operating Room Disposable Surgical Supplies• Dr. Sue Ross, University of Alberta

40

2018 SYMPOSIUM


1030 – 1145 Concurrent Session D4 — Oral Presentations Summit Level, Room 611HEALTH ECONOMICS METHODSFrom 57 to 6 Strategies: Use of Economic Evaluation Methods to Support Appropriate, Affordable, and Accessible Diagnosis of Pulmonary Embolism• Dr. Bernice Tsoi, CADTH

Too Costly to Keep Alive? Equity Concerns Arising From New Economic Evaluation Guidance• Alexander Haines, Toronto Health Economics and Technology Assessment Collaborative (THETA)

Conceptualization, Development, and Internal and External Validation of a Population-Based Microsimulation Model for Chronic Obstructive Pulmonary Disease• Dr. Mohsen Sadatsafavi, University of British Columbia

Integrating 2017 Model-Based Estimates of Hepatitis C Virus (HCV) Prevalence Into the Evaluation of HCV Screening Cost-Effectiveness• Dr. William W.L. Wong, University of Waterloo

Concurrent Session D5 — Oral Presentations Summit Level, Room 603/604OPIOIDSThe Prescription Side of the Opioid Crisis: Supporting New Brunswick Prescribers and Clinicians in Appropriate Use, Monitoring, and Patient Management• Dr. Heidi Liston, New Brunswick Department of Health• Stephanie Smith, CADTH• Dr. Pam Jarrett, Horizon Health Network and New Brunswick Department of Health

Cost-Effectiveness of Hydromorphone for Long-Term Opioid Dependence: Findings From the SALOME Randomized Clinical Trial• Dr. Nick Bansback, University of British Columbia

Migraine Treatment Patterns and Opioid Use Among Chronic and Episodic Migraine Patients Identified by a Clinician-Administered Semi-Structured Diagnostic Interview• Dr. Justin S. Yu, Allergan

Clinical Indications for Initiating Opioids for Pain Management in Ontario, Canada: A Population-Based Cohort Study• Sachin Pasricha, Ontario Drug Policy Research Network

Concurrent Session D6 — Oral Presentations Summit Level, Room 608/609THE PATIENT’S EXPERIENCEThe Reality of Health Technology Access in Canada: Understanding the Patient’s Experience in Drug Coverage Navigation and Early Access Coordination• Mary Lou Robertson, M.L. Robertson Consulting

Patient Voices: Whose Stories Are Missing? Why? And, So What?• Dr. Sharon Batt, Dalhousie University

Using LEAN Tools to Improve the Patient’s Experience• Luciana Lot, University of Campinas, Brazil

Concurrent Session D7 — Oral Presentations Summit Level, Room 605QUALITATIVE EVIDENCEQualitative-Evidence Synthesis and Systematic Review Methods: Merging, Rejecting, Superseding? How Epistemologies and Methodologies Match• Andrea Smith, CADTH

Appraising the Quality of Qualitative Research for Inclusion in Evidence Syntheses: A Compendium of Available Quality-Appraisal Tools• Umair Majid, McMaster University

Rapid Qualitative Reviews: A Scoping Review of Existing Guidance and Published Examples• Dr. Laura Weeks, CADTH

41

2018 SYMPOSIUM


1145 – 1315 AWARDS LUNCHEON Ballroom Level, Ballroom B2/B3This is a plated lunch. Please arrive promptly.

1315 – 1430 Concurrent Session E1 — Panel Discussion Ballroom Level, Room 506/507Health Technology Assessment: Examining Conventional, Complementary, and Traditional Approaches to Health Care• Prof. Devidas Menon, University of Alberta• Dr. Sunita Vohra, University of Alberta• Prof. Heather Boon, University of Toronto• Prof. Amy Bombay, Dalhousie University• Dr. Dugald Seely, Ottawa Integrative Cancer Centre

Concurrent Session E2 — Panel Discussion Summit Level, Room 603-604Can Outcomes-Based Agreements Support Appropriate, Affordable, and Accessible Health Care?• Brad Alyward, MORSE Consulting• Sang Mi Lee, pan-Canadian Pharmaceutical Alliance Office• Fei Fei Liu, Celgene Canada• Dr. Muhammad Mamdani, Li Ka Shing Centre for Healthcare Analytics Research and Training

(CHART), St. Michael’s Hospital

Concurrent Session E3 — Panel Discussion Summit Level, Room 605Beyond Buprenorphine and Methadone: The Role of Emerging Drugs in the Treatment of Opioid Addiction• Dr. Janice Mann, CADTH• Dr. Marie Eve Goyer, Canadian Research Initiative in Substance Misuse, Canadian Society of

Addiction Medicine, and Family Physician• Dr. David Martell, Canadian Society of Addiction Medicine and Family Physician• Jordan Westfall, Canadian Association of People Who Use Drugs

Concurrent Session E4 — Panel Discussion Ballroom Level, Room 501/502Laying the Foundation for a New Health Canada and HTA Alignment: Perspectives on Evidence and Value Assessments From the Health Canada–pCODR (pan-Canadian Oncology Drug Review) Pilot Project • Dr. Heather McDonald, Bayer• Alexandra Chambers, CADTH• Kelly Robinson, Health Canada

Concurrent Session E5 — Panel Discussion Summit Level, Room 608/609As Canadians Consider Adopting National Universal Pharmacare, Will Rare-Disease Therapies Remain Orphans?• John Adams, Canadian PKU, Allied Disorders, and Best Medicines Coalition • Dr. Judith Glennie, PRISM (Promoting Rare-Disease Innovations Through

Sustainable Mechanisms)• Julie Kim, Shire Pharma• Suzanne McGurn, Ontario Ministry of Health and Long-Term Care• Dr. Christopher McMaster, Dalhousie University• Dr. Michael West, Dalhousie University

42

2018 SYMPOSIUM


1315 – 1430 Concurrent Session E6 — Panel Discussion Ballroom Level, Room 503Antimicrobial-Resistance Drugs: From Drug Discovery to Access — Is Canada Prepared for Their Entry?• Dr. Howard Njoo, Public Health Agency of Canada• Dr. Lucye Galand, Health Canada• Dr. Sameeh Salama, Fedora Pharmaceuticals• Dr. Taimur Bhatti, Hoffmann-La Roche (Switzerland)

Concurrent Session E7 — Panel Discussion Summit Level, Room 611The Role of the Patient in HTA and HTM for Precision Medicine Treatment of Lethal and Other Serious Diseases: A National Perspective• Dr. John-Peter Bradford, Life-Saving Therapies Network• Dr. Paul Wheatley-Price, Lung Cancer Canada• Don Husereau, University of Ottawa• Patrick Sullivan, Advocacy for Canadian Childhood Oncology Research Network (Ac2orn)• Sabrina Hanna, Life-Saving Therapies Network• Ken Bond, CADTH

Concurrent Session E8 — Panel Discussion Summit Level, Room 612/613Gene Therapy: Where Is It Headed and How Do We Prepare for It?• Dr. Tammy Clifford, CADTH• Scott Gavura, Cancer Care Ontario• Mark Skinner, World Federation of Hemophilia USA• Helen Trifonopoulos, Novartis Oncology• Dr. Avram Denburg, Hospital for Sick Children• Michèle de Guise, INESSS


1500 – 1615 CLOSING PLENARY Ballroom Level, Ballroom B2/B3Appropriate, Affordable, and Accessible Drug Therapy: Can We Have It All?• Sir Andrew Dillon, Chief Executive of the National Institute for Health and Care Excellence (NICE)• Brian Hilberdink, CEO, Novo Nordisk Canada• Dr. Steve Morgan, Professor, School of Population and Public Health, Faculty of Medicine,

University of British Columbia• Dr. Marianne Taylor, Medical Oncologist• Janet Yale, President and CEO, The Arthritis Society

1615 – 1630 OFFICIAL CLOSING Ballroom Level, Ballroom B2/B3• Dr. Brian O’Rourke, President and CEO, CADTH

44

2018 SYMPOSIUM

46

2018 SYMPOSIUM

COMMITTEESCADTH thanks the members of its Symposium committees for their hard work and tremendous effort.

Program Advisory CommitteeJulia Belliveau

Ken Bond

Alexandra Chambers

Lisa Farrell

Max Iglesias

Chris Kamel

Shannon Kelly

Karen Lee

Michelle Mujoomdar

Sohail Mulla

Jamie Myrah

Lisa Pyke

David Shum

Ingrid Sketris

Amy Sood

Susan Tilley-Russell

Andrea Tiwari

Laura Weeks

Abstract Review CommitteeLusine Abrahamyan

Silvia Alessi-Severini

Meshari Alwashmi

Mubashir Arain

Ruolz Ariste

Afshin Azhir

Teresa Bateman

Brenna Bath

Bruno Battistini

Jennifer G. Daley Bernier

Julia Bidonde

Iwona Bielska

Gord Blackhouse

Ken Bond

Chantal Bourgault

Nancy Butcher

Heather Cameron

Kim Castellano

Jeff Chan

Michael Cheng

Killol Chokshi

Stephen Congly

Doug Coyle

David Dobinson

Peter Dyrda

Mariarosanna De Fina

Zack Dumont

Jesse Elliott

Kukuh Ertjojo

Judith Fisher

Natalie Fitzgerald

Olga Gajic-Veljanoski

Jennifer Glass

Rebeca Isabel Gómez

Luiza Grazziotin

Daniel Grigat

Michael Guirguis

Vida Hamidi

Sharada Harricharan

Stacey Hickson

Mary-Ellen Hogan

Anne Holbrook

Grace Li Ying Huang

Farah Husein

Emma Irvin

Wanrudee Isaranuwatchai

Saadul Islam

Mohammed Jabr

Amer Jarrar

Sarah Jennings

Kate Johnson

Amy Johnston

Liz Keay

Shannon Kelly

Sara Khangura

Rohit Khanna

Joanne Kim

Andrea Kohle

Brent Korte

Seija Kromm

Maude Laberge

Philip la Fleur

Jennifer LaRosa

Avtar Lal

Karen Lee

Teresa Longobardi

Luciana Teixeira Lot

47

2018 SYMPOSIUM

Dandjiu Maëlle

Marina Amaral de Avila Machado

Manouchehr Madani-Civi

Cody Magnusson

Helen Mai

Christine Malmberg

Janice Mann

Lisa Masucci

Nick Mawani

Alain Mayhew

Natalie McCormick

Valerie McDonald

Brendan McIntosh

Annette McKinnon

Devidas Menon

Rebecca Mercer

Jocelyn Milburn

Andriy Moshyk

Michelle Mujoomdar

James Murtagh

Rohini Naipaul

Hai Nguyen

Noelle O’Neill

Shweta Pai

Darren Pasay

Julie Polisena

Michelle Pollock

Yeesha Poon

Shainur Premji

Dale Quest

Valeria Rac

Murali Ramamoorthi

Adam Raymakers

Laurene Redding

Carole Reece

Martin Reed

Angela Rocchi

Stephanie Ross

Dina Salama

Margaret Sampson

Alexis Schaink

Raja B. Singh

Andrea Smith

Maureen Smith

G. Nathalie Sombié

Janet Templeton

Kednapa Thavorn

Leigh-Ann Topfer

Eva Tsakonas

Mon Tun

Leanne Warren

Laura Weeks

Luana Whitbread

David Whitehurst

Durhane Wong-Rieger

Belinda Yap

Man Wah Yeung

Simon Yunger

CADTH Recognition Awards Selection CommitteeDr. Yvonne Bombard

Dr. Fiona Clement

Dr. Irfan Dhalla

Dr. Devidas Menon

Dr. Brian O’Rourke

Dr. Terrence Sullivan

Dr. Laura Weeks

Dr. Harindra Wijeysundera

Symposium ModeratorPeter Chinneck

CADTH Events TeamShannon Kerr

Stephanie Verhey

1650 ARGYLE STREET, HALIFAX, NS

april 15 to 17, 2018, halifax, ns€¦ · symposium participants will be treated to an authentic...

Documents